Ebbe Eldrup

Dr. Ebbe Eldrup


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
TCT.F. Christensen
T.F. Christensen
SCSimon Lebech Cichosz
Simon Lebech Cichosz
LTL. Tarnow
L. Tarnow
JRJ. Randløv
J. Randløv
LKL.E. Kristensen
L.E. Kristensen
OHO.K. Hejlesen
O.K. Hejlesen

15 September 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
EEEbbe Eldrup
Ebbe Eldrup
STSimone Theilade
Simone Theilade
MLMette Lorenzen
Mette Lorenzen
CAChristine Hjorth Andreassen
Christine Hjorth Andreassen
KPKatrine Harpelunde Poulsen
Katrine Harpelunde Poulsen
MJMartin Blomberg Jensen
Martin Blomberg Jensen
Intramuscular Injections of paraffin oil can cause foreign body granuloma formation and hypercalcemia. Macrophages with the ability to produce high levels of 1,25(OH)2D3 may induce the mineral disturbance but no major series of patients have been published to date. Here, medical history, physical evaluation, biochemical and urinary analysis for calcium homeostasis were obtained from 88 males, who 6 years previously had injected paraffin or synthol oil into skeletal muscle. Moreover, granuloma tissue from three men was cultured for 48 hours ex vivo to determine 1,25(OH)2D3‐production supported by qPCR and immunohistochemistry of vitamin D metabolism and immune cell populations following treatment with 14 different drugs. The 88 men were stratified into men with hypercalcemia (34%), while normocalcemic men were separated into men with either normal (42%) or suppressed parathyroid hormone (PTH) (24%). All men had high calcium excretion and nephrolithiasis was found in 48% of hypercalcemic men, 22% of normocalcemic men with normal PTH and 47% of normocalcemic men with suppressed PTH. Risk factors for developing hypercalcemia were oil volume injected, injection of heated oil, high serum interleukin‐2 receptor levels and high urine calcium. High 1,25(OH)2D3/25OHD ratio, calcium excretion and low PTH was associated with nephrolithiasis. The vitamin D activating enzyme CYP27B1 was markedly expressed in granuloma tissue and 1,25(OH)2D3 was released in concentrations corresponding to 40–50% of the production by human kidney specimens. Dexamethasone, Ketoconazole and Ciclosporin significantly suppressed granulomatous production of 1,25(OH)2D3. In conclusion, this study shows that injection of large oil volumes alters calcium homeostasis and increases the risk of nephrolithiasis. Hypercalciuria is an early sign of disease, and high granulomatous 1,25(OH)2D3 production is part of the cause. Prospective clinical trials are needed to determine if Ciclosporin, Ketoconazole or other drugs can be used as prednisolone sparing treatment.

1 January 2022 in Bone
Verified
Journal Article
Open access
SYSam Kafai Yahyavi
Sam Kafai Yahyavi
STSimone Theilade
Simone Theilade
DHDitte Hansen
Ditte Hansen
JBJais Oliver Berg
Jais Oliver Berg
CAChristine Hjorth Andreassen
Christine Hjorth Andreassen
MJMartin Blomberg Jensen
Martin Blomberg Jensen
Granuloma formation following self-administered cosmetic oil injections can lead to severe hypercalcemia and renal calcifications due to extra-renal vitamin D activation. This translational study aims to identify Prednisolone sparing therapeutics for hypercalcemia after development of granulomatous disease secondary to paraffin oil injections. Granuloma tissue isolated from five men were cultured ex vivo and treated with selected drugs to block generation of activated vitamin D (1,25(OH)2D3). In a retrospective study, we included data before and during different treatments of 21 men with paraffin oil induced granulomatous hypercalcemia (46 treatment courses) where serum calcium, parathyroid hormone, vitamin D metabolites, creatinine and inflammatory markers were measured. Addition of Ketoconazole or Ciclosporin to granuloma tissue ex vivo culture, significantly suppressed production of 1,25(OH)2D3 after 48 h (both p < 0.05). Prednisolone was the first treatment option in most men and lowered serum levels of ionized calcium after 1, 2, 3 and 6 months compared with baseline (p < 0.05). Ketoconazole or Hydroxychloroquine had no significant effect on serum calcium levels and were unable to reduce the concomitant daily Prednisolone doses (p > 0.05). Azathioprine did not reduce calcium levels. However, addition of Tacrolimus to Prednisolone treatment enabled a reduction in Prednisolone dose after 3 months (p = 0.014), but with no additional effect on calcium homeostasis. This study verifies that Prednisolone is an effective treatment and suggests that calcineurin inhibitors may be used as Prednisolone sparing treatment for paraffin oil-induced granulomatous hypercalcemia. Randomized clinical trials are needed to determine clinical efficacy.

28 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
LLLotte Lindberg
Lotte Lindberg
BKBent Kristensen
Bent Kristensen
EEEbbe Eldrup
Ebbe Eldrup
JTJane Frølund Thomsen
Jane Frølund Thomsen
LJLars Thorbjørn Jenesn
Lars Thorbjørn Jenesn
Raynaud’s phenomenon (RP) is characterized by the episodic whitening of the fingers upon exposure to cold. A recently described thermographic algorithm was proposed as a diagnostic replacement of the currently applied finger systolic pressure (FSP) test. The aim of the study was to evaluate the performance of the thermographic algorithm when applied in patients suspected of having RP. Forty-three patients were examined using thermographic imaging after local cooling of the hands in water of 10 °C for 1 min. The thermographic algorithm was applied to predict the probability of RP. The performance of the algorithm was evaluated with different cut-off levels. A new algorithm was proposed based on patients from the target population. The performance of the tested algorithm was noninferior to the FSP test, when a cut-off level of 0.05 was applied, yielding a sensitivity and specificity of 69% and 58%, respectively. The accuracy was 66%. The FSP test had a sensitivity and specificity of 77% and 37%, respectively, and the accuracy was 59%. The thermographic method proved useful for detecting RP and was able to replace the FSP test as a diagnostic test. The alternative algorithm revealed that other thermographic variables were more predictive of the target population, but this should be verified in future patients.

20 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
LLLotte Lindberg
Lotte Lindberg
BKBent Kristensen
Bent Kristensen
JTJane F. Thomsen
Jane F. Thomsen
EEEbbe Eldrup
Ebbe Eldrup
LJLars Thorbjørn Jenesn
Lars Thorbjørn Jenesn
Raynaud’s phenomenon (RP) is characterized by the episodic whitening of the fingers upon exposure to cold. Verification of the condition is crucial in vibration-exposed patients. The current verification method is outdated, but thermographic imaging seems promising as a diagnostic replacement. By investigating patients diagnosed with RP, the study aimed at developing a simple thermographic procedure that could be applied to future patients where verification of the diagnosis is needed. Twenty-two patients with primary RP and 58 healthy controls were examined using thermographic imaging after local cooling of the hands for 1 min in water of 10°C. A logistic regression model was fitted with the temperature curve characteristics to convey a predicted probability of having RP. The characteristics time to end temperature and baseline temperature were the most appropriate predictors of RP among those examined (p = 0.004 and p = 0.04, respectively). The area under the curve was 0.91. The cut-off level 0.46 yielded a sensitivity and specificity of 82% and 86%, respectively. The positive and negative predictive values were 69% and 93%, respectively. This newly developed thermographic method was able to distinguish between patients with RP and healthy controls and was easy to operate. Thus, the method showed great promise as a method for verification of RP in future patients. Trial registration: ClinicalTrials.gov NCT03094910.

18 June 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SBSandra L Brandi
Sandra L Brandi
CFClaus L Feltoft
Claus L Feltoft
JSJørgen Serup
Jørgen Serup
EEEbbe Eldrup
Ebbe Eldrup
We describe a married couple who both presented with hypertension and hypokalaemia. Both patients were diagnosed with pseudohyperaldosteronism triggered by the widely used antifungal drug itraconazole. This effect appears to be dose-dependent, where a daily intake of 100 mg itraconazole is enough to induce pseudohyperaldosteronism. Clinicians should be aware of pseudohyperaldosteronism as a possible adverse effect of itraconazole, and we recommend monitoring potassium levels and blood pressure in all patients receiving this drug over a longer period of time. Voriconazole is probably an alternative antifungal treatment to itraconazole but also with this drug potassium levels should be monitored.